** Citi upgrades Healius' HLS.AX rating to "neutral" from "sell" on recent share price decline, the sale of co's unit Lumus Imaging and cost base of its pathology segment reflecting its true business as usual costs
** Brokerage trims price target for co to A$1.05 from A$1.5 to reflect Lumus sale in its forecasts
** Citi forecasts HLS to distribute special dividend of 40 Australian cents/share from sale of Lumus
** The Aussie healthcare firm on Friday shared positive outlook for its pathology business, foreacsting strong growth in 2H
** HLS down ~19.9% YTD as of last close, underperforming against a 3.4% gain on the ASX Health Care index .AXHJ
($1 = 1.5319 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。